Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
08 2023
Historique:
received: 20 02 2023
revised: 19 04 2023
accepted: 27 04 2023
medline: 21 7 2023
pubmed: 13 5 2023
entrez: 12 5 2023
Statut: ppublish

Résumé

Women with hereditary fibrinogen disorders (HFDs) seem to be at an increased risk of adverse obstetrical outcomes, but epidemiologic data are limited. We aimed to determine the prevalence of pregnancy complications; the modalities and management of delivery; and the postpartum events in women with hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia. We conducted a retrospective and prospective multicentric international study. A total of 425 pregnancies were investigated from 159 women (49, 95, and 15 cases of hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia, respectively). Overall, only 55 (12.9%) pregnancies resulted in an early miscarriage, 3 (0.7%) resulted in a late miscarriage, and 4 (0.9%) resulted in an intrauterine fetal death. The prevalence of live birth was similar among the types of HFDs (P = .31). Obstetrical complications were observed in 54 (17.3%) live birth pregnancies, including vaginal bleeding (14, 4.4%), retroplacental hematoma (13, 4.1%), and thrombosis (4, 1.3%). Most deliveries were spontaneous (218, 74.1%) with a vaginal noninstrumental delivery (195, 63.3%). A neuraxial anesthesia was performed in 116 (40.4%) pregnancies, whereas general or no anesthesia was performed in 71 (16.6%) and 129 (44.9%) pregnancies, respectively. A fibrinogen infusion was administered in 28 (8.9%) deliveries. Postpartum hemorrhages were observed in 62 (19.9%) pregnancies. Postpartum venous thrombotic events occurred in 5 (1.6%) pregnancies. Women with hypofibrinogenemia were at an increased risk of bleeding during the pregnancy (P = .04). Compared with European epidemiologic data, we did not observe a greater frequency of miscarriage, while retroplacental hematoma, postpartum hemorrhage, and thrombosis were more frequent. Delivery was often performed without locoregional anesthesia. Our findings highlight the urgent need for guidance on the management of pregnancy in HFDs.

Sections du résumé

BACKGROUND
Women with hereditary fibrinogen disorders (HFDs) seem to be at an increased risk of adverse obstetrical outcomes, but epidemiologic data are limited.
OBJECTIVES
We aimed to determine the prevalence of pregnancy complications; the modalities and management of delivery; and the postpartum events in women with hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.
METHODS
We conducted a retrospective and prospective multicentric international study.
RESULTS
A total of 425 pregnancies were investigated from 159 women (49, 95, and 15 cases of hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia, respectively). Overall, only 55 (12.9%) pregnancies resulted in an early miscarriage, 3 (0.7%) resulted in a late miscarriage, and 4 (0.9%) resulted in an intrauterine fetal death. The prevalence of live birth was similar among the types of HFDs (P = .31). Obstetrical complications were observed in 54 (17.3%) live birth pregnancies, including vaginal bleeding (14, 4.4%), retroplacental hematoma (13, 4.1%), and thrombosis (4, 1.3%). Most deliveries were spontaneous (218, 74.1%) with a vaginal noninstrumental delivery (195, 63.3%). A neuraxial anesthesia was performed in 116 (40.4%) pregnancies, whereas general or no anesthesia was performed in 71 (16.6%) and 129 (44.9%) pregnancies, respectively. A fibrinogen infusion was administered in 28 (8.9%) deliveries. Postpartum hemorrhages were observed in 62 (19.9%) pregnancies. Postpartum venous thrombotic events occurred in 5 (1.6%) pregnancies. Women with hypofibrinogenemia were at an increased risk of bleeding during the pregnancy (P = .04).
CONCLUSION
Compared with European epidemiologic data, we did not observe a greater frequency of miscarriage, while retroplacental hematoma, postpartum hemorrhage, and thrombosis were more frequent. Delivery was often performed without locoregional anesthesia. Our findings highlight the urgent need for guidance on the management of pregnancy in HFDs.

Identifiants

pubmed: 37172732
pii: S1538-7836(23)00396-3
doi: 10.1016/j.jtha.2023.04.035
pii:
doi:

Substances chimiques

Fibrinogen 9001-32-5
Hemostatics 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2126-2136

Informations de copyright

Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests A.C. reports grants and fees paid to his institution from CSL Behring, Octapharma, Sobi, LFB, Takeda, and Novo Nordisk. A.L. reports grants and fees from Octapharma and LFB. C.L.B reports receiving grants and fees from LFB, Octapharma, CSL Behring, and Novo Nordisk. M.F. reports grants and fees from LFB. All other authors have no competing interests to disclose.

Auteurs

Justine Hugon-Rodin (J)

Gynecology Department, Gynecological Endocrinology Unit, Hospital Saint Joseph, INSERM UMR 1153, EPOPé Group, Paris, France; University Hospitals of Geneva and the Faculty of Medicine of the Geneva University, DFEA-Ob/Gyn-reproductive medicine, Geneva, Switzerland.

Camille Carrière (C)

Gynecology Department, Bigorre Hospital Center, Tarbes, France.

Ségolène Claeyssens (S)

Haemophilia Treatment Centre, University Hospital, Toulouse, France.

Nathalie Trillot (N)

Department of Hemostasis and Transfusion, CHU Lille, Lille, France.

Nicolas Drillaud (N)

Haemophilia Treatment Centre, University Hospital, Nantes, France.

Christine Biron-Andreani (C)

Haemophilia Treatment Centre, University Hospital, Montpellier, France.

Cécile Lavenu-Bombled (C)

Service d'hématologie biologique, Centre de Ressources et Compétences Maladies Constitutionnelles rares, CHU Bicêtre, AP-HP, Paris, France; Faculty of Medicine, Université Paris-Saclay, Paris, France; UMR S1176 INSERM, Le Kremlin-Bicêtre, Paris, France.

Anna Wieland (A)

Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Switzerland.

Claire Flaujac (C)

Laboratoire de biologie médicale, secteur Hémostase, Centre Hospitalier de Versailles (André Mignot), Le Chesnay, France.

Natalie Stieltjes (N)

Haemophilia Treatment Center, Cochin Hospital, AP-HP, Paris, France.

Aurélien Lebreton (A)

Service d'hématologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Thomas Brungs (T)

Haemostasis and Thrombosis Unit, CHR Orleans, Orleans, France.

Andrea Hegglin (A)

Department of Hematology, Luzerner Kantonsspital, Lucerne, Switzerland.

Mathieu Fiore (M)

Laboratoire d'hématologie, Hôpital cardiologique du Haut-Lévêque, CHU de Bordeaux, Bordeaux, France; INSERMU1034, Biologie des Maladies Cardio-Vasculaires, Université de Bordeaux, Pessac, France.

Céline Desconclois (C)

Biological Hematology, Antoine Béclère Hospital, AP-HP, Paris, France; Paris-Saclay University, Clamart, France.

Valérie Gay (V)

Hemophilia Treatment Center, Hospital, Chambéry, France.

Brigitte Tardy-Poncet (B)

Centre de Ressources et de Compétence Maladies hémorragiques, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France; INSERM CIC 1408, Saint-Etienne, CHU Saint-Etienne Hôpital Nord, Saint-Etienne, France; SAINBIOSE, INSERM U1059, Université Lyon, Saint-Etienne, France.

Philippe Beurrier (P)

Hemophilia Treatment Center, Vascular and Coagulation Clinic, University Hospital Angers, France.

Virginie Barbay (V)

Haemophilia Treatment Centre, University Hospital, Rouen, France.

Pierre Chamouni (P)

Haemophilia Treatment Centre, University Hospital, Rouen, France.

Emmanuel De Maistre (E)

CRC Maladies Hémorragiques Constitutionnelles, CHU Dijon, Dijon, France.

Tomas Simurda (T)

National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Slovakia.

Alessandro Casini (A)

Division of Angiology and Hemostasis, University Hospitals of Geneva, Faculty of Medicine, Geneva, Switzerland. Electronic address: alessandro.casini@hcuge.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH